Final results of multicenter phase Ib/ II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BiTS study).

Masato Nakamura,Hironaga Satake,Koji Oba,Masahito Kotaka,Yoshinori Kagawa,Hisateru Yasui,Takanori Watanabe,Toshihiko Matsumoto,Takayuki Kii,Tetsuji Terazawa,Akitaka Makiyama,Nao Takano,Mitsuru Yokota,Yoshihiro Okita,Koreatsu Matoba,Hiroko Hasegawa,Akihito Tsuji,Naoki Nagata,Junichi Sakamoto,Takeshi Kato

Final results of multicenter phase Ib/ II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BiTS study).

2020

121Background: We have conducted the multicenter, phase Ib/II study to assess the activity and safety of biweekly Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) combination for pts with me...

Keywords:

Internal medicine
Medicine
Oncology
Bevacizumab
Pathology
Refractory
Tipiracil
Trifluridine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations